Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2021 Financial Results and Recent Business Highlights
— Positive Results from Phase 2 Clinical Study of PL9643 in Patients with Dry Eye Disease — Continue to Rebuild Commercial Infrastructure and Brand Awareness for Vyleesi® — Approximately $72.2 Million in Cash and Cash Equivalents at December 31, 2020 — Teleconference and Webcast to be held on February 17, 2021 at 11:00 AM ET …